Search results
Results from the WOW.Com Content Network
In July 2021, the U.S. Food and Drug Administration (FDA) approved Tanovea to treat lymphoma in dogs. [6] Lymphoma, also called lymphosarcoma, is a type of cancer that can affect many species, including dogs. [6] Rabacfosadine is the first conditionally approved new animal drug for dogs to achieve the FDA's full approval. [6]
In 2022, the capsid inhibitor Lenacapavir received approval from the European Medicines Agency, Health Canada, and the United States Food and Drug Administration as a first-in-class medication to treat HIV-1 infection.
Lenacapavir was approved for medical treatment in the European Union in August 2022, [10] [12] in Canada in November 2022, [5] [6] and in the United States in December 2022. [9] [11] [13] [14] It is the first of a class of drugs called capsid inhibitors to be approved by the US Food and Drug Administration (FDA) for treating HIV/AIDS. [11] [15]
Here’s what you need to know about Leqembi, the latest treatment on the market. ... FDA approval of Leqembi: U.S. Food and Drug Administration Leqembi study: New England Journal of Medicine
(Reuters) -The U.S. Food and Drug Administration on Tuesday approved Johnson & Johnson's chemotherapy-free combination treatment for a type of non-small cell lung cancer, setting up a challenge ...
Avelumab is FDA approved for the treatment of metastatic merkel-cell carcinoma. It failed phase III clinical trials for gastric cancer. [33] Durvalumab (Imfinzi) is a fully human IgG1 antibody developed by AstraZeneca. Durvalumab is FDA approved for the treatment of urothelial carcinoma and unresectable non-small cell lung cancer after ...
The FDA said the cancer treatment may raise the risk of secondary cancers. ... The first CAR-T therapy, Novartis’ drug Kymriah, received FDA approval in 2017. Since then, another five have been ...
Molidustat is a drug which acts as an HIF prolyl-hydroxylase inhibitor and thereby increases endogenous production of erythropoietin, which stimulates production of hemoglobin and red blood cells. It is in Phase III clinical trials for the treatment of anemia caused by chronic kidney disease.